Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP-C1 in Stage IV Breast Cancer
NCT04298333Phase 1Completed
- Sponsor
- Meabco A/S
- Start
- Jun 2009
- Primary completion
- Jan 2011
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of BP-C1 in breast cancer, sponsored by Meabco A/S. Primary endpoints: Change in Maximum Common Terminology Criteria (CTC) score for Adverse Events at Day 60 and Sum Common Terminology Criteria (CTC) score for Adverse Events at Day 60. Started Jun 2009; status: completed.
02
Drugs
BP-C1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04298333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298333.